Osteoporosis Drug Complications Linked To Genetic Factors
According to a study published in the online version of the journal The Oncologist, a genetic variation that increases the risk of individuals who take bisphosphonates, developing serious necrotic jaw bone lesions, has been identified by researchers at the Columbia University College of Dental Medicine. Bisphosphonates are a common class of osteoclastic inhibitors that work by attaching to calcium in the bone and inhibiting osteoclasts, bone cells that disintegrate the bone's mineral structure.
Leukemia Cells Are Bad To The Bone
University of Rochester Medical Center researchers have discovered new links between leukemia cells and cells involved in bone formation, offering a fresh perspective on how the blood cancer progresses and raising the possibility that therapies for bone disorders could help in the treatment of leukemia. The research, led by graduate student Benjamin J. Frisch in the James P. Wilmot Cancer Center laboratory of corresponding author Laura M. Calvi, M.D., is featured in the journal Blood. It is accompanied by an editorial - "Bad to the Bone" - written by another leading investigator in the field, Steven W.
Position Statement On The Role Of Vitamin D In Postmenopausal Women Published In Maturitas
Elsevier, a world-leading provider of scientific, technical and medical information products and services, has announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) in journal Maturitas on the role of vitamin D in postmenopausal women with summary recommendations. Vitamin D deficiency is common and may affect up to 70% of Europeans. It is classified as a public health issue as it can contribute to many diseases, especially osteoporosis. EMAS has risen to the challenge of increasing awareness of vitamin D deficiency to women and health professionals.